Skip to content

tACS for Working Memory in Schizophrenia

Efficacy and Mechanisms of Transcranial Alternating Current Stimulation in Improving Working Memory in Patients With Schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07701343
Enrollment
30
Registered
2026-07-14
Start date
2026-07-06
Completion date
2026-12-31
Last updated
2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, Working Memory

Keywords

Schizophrenia, Working Memory, Transcranial Alternating Current Stimulation

Brief summary

This study is a randomized, single-blind, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the efficacy and mechanisms of individualized alpha-tACS on working memory.

Detailed description

This study is a randomized, single-blind, sham-controlled, crossover exploratory trial that plans to enroll 30 inpatients with schizophrenia, randomized 1:1 into two groups, with all participants receiving one active and one sham tACS session in a crossover manner separated by a 7-day washout. Stimulation targets the parietal P3/P4 sites at individual alpha frequency, with an intensity of 2 mA and a duration of 30 minutes per session, delivered concurrently with a working memory task (SIRP). Primary outcomes are SIRP accuracy and reaction time, with concurrent task-state EEG recording, along with assessments of clinical symptoms, cognitive function, and neurophysiological markers including ASSR, MMN, and P300. The study aims to explore the efficacy and underlying neural mechanisms of individualized alpha-tACS in improving working memory in schizophrenia.

Interventions

DEVICEtranscranial alternating current stimulation

For montage 1, active electrode at P3 (10-10 system), return electrodes at P1, P5, PO3, CP3. For montage 2, active electrode at P4, return electrodes at P2, P6, PO4, CP4. Conductive paste ensures impedance \<10 kΩ. Individual alpha frequency is used, calculated before each session from mean EEG at P3/P4 during SIRP task. Stimulation intensity is 2 mA (peak-to-zero) via electric field modeling. Stimulation is delivered during SIRP task, 30 min total per session (including 15s ramp-up/down), with continuous sine wave output.

DEVICEsham stimulation

Sham stimulation provides only a 15-second ramp-up and ramp-down current at the beginning and end of each session to mimic the initial tingling or itching sensation on the scalp produced by real stimulation, but delivers no effective stimulation current during the main phase of the task period.

Sponsors

Central South University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

This study used a single-blind design, with participants blinded to treatment allocation (active vs. sham). The device operator was not blinded due to differing parameter settings between active and sham stimulation, but was not involved in recruitment, clinical assessment, or data analysis. To maintain blinding integrity, participants were prohibited from discussing treatment-related sensations with the operator or among themselves. The sham procedure mimicked the initial scalp sensation of active stimulation to enhance blinding credibility.

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18-50 years, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5). * Spatial span T-score \<40 on the MATRICS Consensus Cognitive Battery (MCCB). * Taking 1-2 antipsychotic medications, with stable dosage for at least 1 week prior to enrollment. No use of mood stabilizers, antidepressants, or excessive benzodiazepines (lorazepam equivalent \>2 mg/day). The type and dosage of antipsychotic medications remain unchanged during the treatment period. * Impaired functioning in daily activities. * Willing to participate in this study and provide written informed consent.

Exclusion criteria

* Previously diagnosed with or comorbid any other DSM-5 mental disorder besides schizophrenia. * Presence of significant mood symptoms or substance use disorder (other than caffeine and/or tobacco). * Presence of any contraindication to transcranial alternating current stimulation (tACS). * Received other forms of electrical or magnetic stimulation therapy within 1 month prior to enrollment. * History or current presence of any major physical illness, neurological disorder, or traumatic brain injury that may affect brain structure or function. * Pregnant or breastfeeding women, or women planning to become pregnant during the study period.

Design outcomes

Primary

MeasureTime frameDescription
Working Memory AccuracyDay 1 (baseline, prior to first intervention); within 15 minutes after Session 1; Day 9 (prior to second intervention, after 7-day washout); within 15 minutes after Session 2.Assessment of task accuracy on the Sternberg Item Recognition Paradigm (SIRP). Participants are required to judge whether a probe stimulus belongs to a previously memorized set, with memory set sizes of 1 and 5. The outcome is measured as the percentage of correct responses (0-100%) across all trials, with higher scores indicating better working memory performance.
Working Memory Reaction TimeDay 1 (baseline, prior to first intervention); within 15 minutes after Session 1; Day 9 (prior to second intervention, after 7-day washout); within 15 minutes after Session 2.Assessment of response speed on the Sternberg Item Recognition Paradigm (SIRP). Participants are required to judge whether a probe stimulus belongs to a previously memorized set, with memory set sizes of 1 and 5. The outcome is measured as the mean response latency for correct responses only, calculated from stimulus onset to the participant's button press, with shorter times indicating faster processing speed.

Secondary

MeasureTime frameDescription
Changes in MCCB PerformanceBaseline, on the day after each of the two interventionsAssessment of cognitive function using the MATRICS Consensus Cognitive Battery (MCCB), a standardized cognitive assessment tool designed for schizophrenia and other neuropsychiatric conditions. The MCCB evaluates 9 cognitive domains: attention, information processing speed, verbal learning and memory, visual learning and memory, spatial working memory, reasoning and problem solving, social cognition, executive function, and fine motor skills. The overall cognitive composite score ranges from 20 to 100 (T-score), with higher scores indicating better cognitive performance.
Changes in Positive and Negative Symptom Scale (PANSS) ScoresBefore and one week after each of the two interventions.Scores range from 30 to 210, with higher scores indicating more severe positive and negative symptoms.
Changes in Scale for the Assessment of Negative Symptoms (SANS) ScoresBefore and one week after each of the two interventions.Scores range from 0 to 120; higher scores indicate more severe negative symptoms.
Changes in Calgary Depression Scale for Schizophrenia (CDSS) ScoresBefore and one week after each of the two interventions.Scores range from 0 to 27; higher scores indicate more severe affective symptoms.
Changes in Brain FunctionBaseline, on the day after each of the two interventions.Functional magnetic resonance imaging (fMRI), based on blood oxygen level-dependent (BOLD) contrast, can detect changes in blood oxygenation and analyze changes in brain function after intervention.
Changes in Neuroelectrophysiological SignalsBaseline, 30 minutes after each of the two interventions.Changes in neuroelectrophysiological signals are collected through task-based electroencephalography (EEG).
Changes in 40Hz Auditory Steady-State Response (40Hz-ASSR)Baseline, 30 minutes after each of the two interventions.The 40Hz auditory steady-state response recorded by EEG, including evoked power and inter-trial phase coherence, will be measured. The unit of measurement for evoked power is μV², and for coherence is unitless.
Changes in Mismatch Negativity (MMN)Baseline, 30 minutes after each of the two interventions.Mismatch negativity amplitude recorded by EEG using an oddball paradigm will be measured. The unit of measurement is microvolts (μV).
Changes in P300 Event-Related PotentialBaseline, 30 minutes after each of the two interventions.P300 amplitude recorded by EEG using an oddball paradigm will be measured. The unit of measurement is microvolts (μV).
Hallucination and Delusion Visual Analog Scale (HD-VAS) ScoreWithin 15 minutes after completion of Session 1; within 15 minutes after completion of Session 2.Assessment of acute post-intervention changes in hallucination and delusion severity using a patient-rated visual analog scale (VAS). The scale consists of a 0-100 mm horizontal line, on which participants mark their current symptom severity. The distance (in millimeters) from the left anchor ("no symptoms") to the participant's mark is measured with a ruler. This scale serves as a supplementary measure to the PANSS to capture immediate symptom changes following each intervention. Scores range from 0 to 100 mm, with higher scores indicating more severe hallucinations and delusions.

Countries

China

Contacts

CONTACTRenrong Wu
wurenrong@csu.edu.cn15874179855

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026